Activist Investor 3i, LP Demands Immediate Removal of Valion Bio CEO
VBIO sits 26% above its 52-week low of $0.251 on elevated volume (6.5× avg).
Summary
Valion Bio's largest shareholder, 3i, LP, publicly demands the immediate removal of CEO Michael Handley, accusing him of destroying shareholder value and warning the board of fiduciary breaches.
Key Events · Executive and Board Changes · VBIO
-
Activist Demands CEO Removal
3i, LP, holding 9.9% of Valion Bio, sent a letter to the board on July 29, 2026 demanding the immediate removal of CEO Michael Handley for 'sustained mismanagement' and warning of potential director liability.
-
Investor Sells While Demanding Change
Despite the activist stance, 3i, LP sold a net ~$50k of shares in the past 60 days, while affiliate Tumim Stone sold a net ~$300k, raising questions about alignment.
-
Recent Preferred Conversions Add Pressure
3i, LP converted 256,105 shares of Series B Preferred Stock on July 19 at $0.3769, increasing its common stake just days before the demand letter.
-
Board Under Fire Amid Financial Distress
The demand comes as Valion Bio faces a going-concern warning, a pending reverse stock split vote, and a cash runway measured in months, intensifying governance risks.
Analysis · VBIO · Life Sciences
A 9.9% holder with deep financial ties to Valion Bio, 3i, LP, has gone public with a blistering letter demanding the board fire CEO Michael Handley immediately. The letter accuses Handley of 'sustained mismanagement' and warns directors of potential liability for inaction. This is not a quiet behind-the-scenes push — it's a public shot across the bow that signals a breakdown in the relationship between the company and its most important financial backer. The filing also reveals that 3i and its affiliate Tumim Stone have been net sellers of stock over the past two months, even as they demand leadership change, which complicates the narrative. For a micro-cap biotech already fighting a going-concern warning and seeking a reverse split, a public CEO-removal demand from its largest investor adds a new layer of uncertainty and potential boardroom turmoil.
At the time of this filing, VBIO was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.25 to $5.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.